Hormonal
GLP-1 receptor agonists (liraglutide, semaglutide) and dual GIP/GLP-1 agonists (tirzepatide) produce significant weight loss (5-15%) and improve cardiometabolic risk factors in adults with obesity, with efficacy increasing with higher doses.
If lifestyle changes alone haven't led to significant weight loss, GLP-1 or dual agonist medications can help you lose 5-15% of your body weight and improve your blood sugar and heart health. These are prescription medications that work by mimicking hormones that control hunger. You will need to start with a low dose and slowly increase it to avoid stomach side effects like nausea.
Saxenda® 3.0 mg... confirmed significant average weight loss... SCALE Obesity and Prediabetes study 8.0% [placebo 2.6%]... STEP 1... semaglutide 2.4 mg... average 12.4% weight loss... SURPASS-1... tirzepatide 5 mg, 10 mg, 15 mg... HbA1c reduction 1.91%, 1.93%, 2.11%
Why this rating
Multiple large-scale, randomized, placebo-controlled Phase 3 clinical trials (EQUIP, CONQUER, SCALE, STEP, SURPASS) are cited.
Source
Recent Advances in Anti-Obesity Drugs
Jang Won Son · Journal of Korean Diabetes · 2022
DOI 10.4093/jkd.2022.23.2.113
More from this paper
- Phentermine/topiramate combination therapy produces significant weight loss (up to 8.6% vs placebo) and improves metabolic markers, but is contraindicated in patients with unstable cardiovascular disease.Strong
- Naltrexone/bupropion combination therapy produces moderate weight loss (up to 6.1% vs placebo) and improves metabolic markers, but carries risks of seizures and psychiatric side effects.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →